Perspectives for malaria vaccination.
The need for vaccines to relieve the current global resurgence of malaria is apparent. Immunity is specific for each species of human malaria and for each stage in the life cycle. Once protective immunogens have been identified for one species, the homologous molecules in other species may lead to protection. The usefulness of a particular immunogen will be determined, in part, by its antigenic diversity in the population and the potential for boosting during natural infection. Successful immunization with malarial antigens may require adjuvants to induce effective, long-lived immunity. If different vaccines become available against each stage in the life cycle, then the composition of a particular vaccine may be tailored for different objectives: protection for short periods (for example, during epidemics and for tourists), decrease in disease and death, and malaria eradication.
D000818:Animals; D000911:Antibodies, Monoclonal; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology; D004274:DNA, Recombinant; D004910:Erythrocyte Membrane / Q000276:immunology; D014644:Genetic Variation; D006801:Humans; D007109:Immunity; D008099:Liver / Q000276:immunology; D008288:Malaria / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D010961:Plasmodium / Q000254:growth & development / Q000276:immunology; D014611:Vaccination
D000911:Antibodies, Monoclonal; D000953:Antigens, Protozoan; D004274:DNA, Recombinant